All In Biotech

Drug Trial Radar · NCT04516447

A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer

A Phase 1b Study of ZN-c3 in Combination With Chemotherapy or Bevacizumab in Subjects With Ovarian, Peritoneal, or Fallopian Tube Cancer

Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

172

Planned (sponsor's estimate)

Start

Oct 26, 2020

Primary completion

Jun 30, 2028

Study completion Jun 30, 2028

Sponsor

Sponsor type
Industry
First posted
Aug 18, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1b open-label, multicenter study, evaluating the safety, tolerability, preliminary clinical activity, pharmacokinetics (PK), and pharmacodynamics of azenosertib (ZN-c3) in combination with other drugs.

Conditions

  • Solid Tumor
  • Epithelial Ovarian Cancer
  • Fallopian Tube Cancer
  • Peritoneal Cancer

Interventions

  • AzenosertibDrug

    Investigational drug

  • CarboplatinDrug

    Carboplatin is an approved drug

  • Pegylated liposomal doxorubicinDrug

    Pegylated liposomal doxorubicin (PLD) is an approved drug

  • PaclitaxelDrug

    Paclitaxel is an approved drug

  • GemcitabineDrug

    Gemcitabine is an approved drug

  • BevacizumabBiological

    Bevacizumab is an approved drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: To investigate the safety and tolerability of azenosertib in combination with PLD, carboplatin, paclitaxel, or gemcitabineTime frame: Through study completion, an average of 1 year
  2. Part 1: To identify the maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D) of azenosertib in combination with PLD, carboplatin, paclitaxel, or gemcitabineTime frame: Through Cycle 1 (cycle is 28 days for PLD or paclitaxel, and 21 days for carboplatin, or gemcitabine)
  3. Part 2: To estimate the safety/tolerability of azenosertib in combination with bevacizumabTime frame: Through study completion, an average of 1 year
  4. Part 2: To identify the recommended dose for Part 2 Dose ExpansionTime frame: Through Cycle 1 (21 days)

Locations

35 sites in 8 countries. Site status is shown where the registry gives one.

  • Site 0264

    Aurora, Colorado · Active not recruiting

  • Site 0104

    Boston, Massachusetts · Recruiting

  • Site 0111

    St Louis, Missouri · Recruiting

  • Site 0173

    New York, New York · Recruiting

  • Site 0259

    Durham, North Carolina · Recruiting

  • Site 0191

    Providence, Rhode Island · Recruiting

  • Site 0196

    Nashville, Tennessee · Completed

  • Site 0103

    Houston, Texas · Recruiting

  • Site 2707

    South Brisbane, Queensland, Australia · Completed

  • Site 2708

    Sunshine Coast, Queensland, Australia · Completed

  • Site 2718

    Sunshine Coast, Queensland, Australia · Recruiting

  • Site 2709

    Adelaide, South Australia, Australia · Completed

  • Site 2716

    Melbourne, Victoria, Australia · Recruiting

  • Site 2706

    Melbourne, Victoria, Australia · Completed

  • Site 2705

    Nedlands, Western Australia, Australia · Completed

  • Site 1001

    Banja Luka, Bosnia and Herzegovina · Completed

  • Site 1002

    Sarajevo, Bosnia and Herzegovina · Completed

  • Site 1003

    Tuzla, Bosnia and Herzegovina · Completed

  • Site 1202

    Panagyurishte, Bulgaria · Completed

  • Site 1201

    Sofia, Bulgaria · Completed

  • 3613

    Besançon, France · Not yet recruiting

  • 3624

    Bordeaux, France · Recruiting

  • 3601

    Dijon, France · Recruiting

  • 3608

    Lyon, France · Not yet recruiting

  • 3614

    Nantes, France · Not yet recruiting

  • 3623

    Paris, France · Not yet recruiting

  • 3604

    Paris, France · Not yet recruiting

  • 3625

    Rennes, France · Recruiting

  • 3611

    Strasbourg, France · Not yet recruiting

  • 3603

    Toulouse, France · Recruiting

  • Site 1401

    Tbilisi, Georgia · Completed

  • Site 1902

    Belgrade, Serbia · Completed

  • Site 2901

    Busan, South Korea · Completed

  • Site 2903

    Seoul, South Korea · Completed

  • Site 2904

    Seoul, South Korea · Completed

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.